ZIOPHARM’s gene therapy candidate Ad-RTS-hIL-12 shows positive effect in treatment-resistant brain cancer in early … – Seeking Alpha
Boston Business Journal |
ZIOPHARM's gene therapy candidate Ad-RTS-hIL-12 shows positive effect in treatment-resistant brain cancer in early …
Seeking Alpha ZIOPHARM (NASDAQ:ZIOP) is up 13% premarket on average volume on the heels of its announcement of positive results from a Phase 1 clinical trial assessing Ad-RTS-hIL-12 + veledimex in patients with recurrent glioblastoma (rGBM). The data were … Ziopharm says its brain cancer drug helped trial patients live more than a year |
